Company: INMB
Filing Date: 2025-06-30
Form Type: 424B5
Source: 0001213900-25-059298
Chunk: 16

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 424B5
Chunk 16
---
 outstanding. The outstanding shares of common stock are validly issued, fully paid and nonassessable.

Holders of common stock are
entitled to one vote for each share on all matters submitted to a stockholder vote. Holders of common stock do not have cumulative voting
rights. Holders of a plurality of the shares of common stock voting for the election of directors can elect all of the directors. Holders
of common stock representing 33.3% of the voting power of our capital stock issued, outstanding and entitled to vote, represented in person
or by proxy, are necessary to constitute a quorum at any meeting of stockholders.

Holders of common stock are
entitled to share in all dividends that our board of directors, in its discretion, declares from legally available funds. In the event
of a liquidation, dissolution or winding up, each outstanding share entitles its holder to participate pro rata in all assets that remain
after payment of liabilities and after providing for each class of stock, if any, having preference over the common stock. The common
stock has no pre-emptive, subscription or conversion rights and there are no redemption provisions applicable to the common stock.

<div align='center'>S-10

PLAN OF DISTRIBUTION</div>

A.G.P.
has agreed to act as our placement agent in connection with this offering subject to the terms and conditions of the Placement Agency
Agreement dated June 27, 2025. The Placement Agent is not purchasing or selling any of the securities offered by this prospectus supplement,
nor is it required to arrange the purchase or sale of any specific number or dollar amount of securities, but has agreed to use its reasonable
best efforts to arrange for the sale of all of the securities offered hereby. We will enter into a securities purchase agreement directly
with the investors who purchase our securities in this offering. We may not sell the entire amount of securities offered pursuant to this
prospectus.

We
will deliver the securities being issued to the investors upon receipt of such investor’s funds for the purchase of the securities
offered pursuant to this prospectus supplement. We expect to deliver the securities being offered pursuant to this prospectus supplement
on or about June 30, 2025, subject to the satisfaction of customary closing conditions.

We
have agreed to indemnify the Placement Agent against specified liabilities, including liabilities under the Securities Act of 1933, as
amended (the “Securities Act”), and to contribute to payments the